Samsung Medical Center Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Organization Overview

First Clinical Trial
2012
NCT01738100
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Ophthalmology, Samsung Medical Center | Department of Otorhinolaryngology, Samsung Medical Center | Department of Pediatrics Samsung Medical Center and Sungkyunkwan University School of Medicine | Duk Lyul Na | Heart Vascular Stroke Institute, Samsung Medical Center | Hyeon-Cheol Gwon | Jooheung Lee | Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea | Keunchil Park | Kim, Seok Jin | Myung-Ju Ahn | Samsung medical center, Emergency department | Samsun Research and Education Hospital | samsun university, samsun training and research hospital | Se-Hoon Lee | Yae-Jean Kim | Yoo-Sook Joung | Yun-Hee Kim

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autistic Disorder (Phase 4)

Communicable Diseases (Phase 2)

Cytomegalovirus Infections (Phase 2)

Infarction (Phase 2)

Infections (Phase 2)

Lymphoma (Phase 2)

Myocardial Infarction (Phase 2)

Neoplasms (Phase 1)

Psoriasis (Phase 4)

Small Cell Lung Carcinoma (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 19